Reversal of Neuromuscular Blockade with Sugammadex Based on the Residual of Rocuronium in the Body

Trial Profile

Reversal of Neuromuscular Blockade with Sugammadex Based on the Residual of Rocuronium in the Body

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2015

At a glance

  • Drugs Sugammadex (Primary) ; Rocuronium bromide
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
    • 15 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top